(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of -32.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Kymera Therapeutics's revenue in 2026 is $104,999,000.On average, 25 Wall Street analysts forecast KYMR's revenue for 2026 to be $7,404,229,930, with the lowest KYMR revenue forecast at $3,398,033,155, and the highest KYMR revenue forecast at $11,262,751,208. On average, 25 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,554,855,221, with the lowest KYMR revenue forecast at -$1,059,338,873, and the highest KYMR revenue forecast at $8,550,378,049.
In 2028, KYMR is forecast to generate $3,389,136,039 in revenue, with the lowest revenue forecast at -$2,037,190,141 and the highest revenue forecast at $7,121,434,679.